^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
SalMet-Vec (SGN1)
i
Other names: SGN1, genetically modified strain of Salmonella enterica
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Sinogen Pharma
Drug class:
Immunostimulant
Related drugs:
3ms
Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor (clinicaltrials.gov)
P1/2, N=70, Recruiting, Guangzhou Sinogen Pharmaceutical Co., Ltd | N=50 --> 70 | Trial completion date: Oct 2025 --> Jun 2028 | Trial primary completion date: Apr 2025 --> Dec 2027
Enrollment change • Trial completion date • Trial primary completion date • Metastases
|
SalMet-Vec (SGN1)
3ms
Study of SGN1 in Patients With Advanced Solid Tumor (clinicaltrials.gov)
P1/2, N=70, Recruiting, Guangzhou Sinogen Pharmaceutical Co., Ltd | N=50 --> 70 | Trial completion date: Aug 2024 --> Aug 2028 | Trial primary completion date: Feb 2024 --> Jan 2028
Enrollment change • Trial completion date • Trial primary completion date • Metastases
|
SalMet-Vec (SGN1)
3ms
Salmonella-mediated methionine deprivation drives immune activation and enhances immune checkpoint blockade therapy in melanoma. (PubMed, J Immunother Cancer)
Patients in cluster 2 had higher expression of methionine_deprivation_up genes, better clinical outcomes, and higher immune infiltration levels compared with patients in cluster 1. Western blot, IPS analysis, and immunotherapy cohort study revealed that methionine deficiency may show a better response to ICI therapy CONCLUSIONS：: This study reports Salmonella-based SGN1 as a potent anticancer agent against melanoma, and lays the groundwork for the potential synergistic effect of ICIs and SGN1 brought about by improving the immune microenvironment in melanomas.
Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker • Checkpoint block
|
CD8 (cluster of differentiation 8)
|
SalMet-Vec (SGN1)
7ms
Study of SGN1 in Patients With Advanced Solid Tumor (clinicaltrials.gov)
P1/2, N=50, Recruiting, Guangzhou Sinogen Pharmaceutical Co., Ltd | Phase classification: P1 --> P1/2
Phase classification • Metastases
|
IL6 (Interleukin 6)
|
SalMet-Vec (SGN1)
7ms
Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor (clinicaltrials.gov)
P1/2, N=50, Recruiting, Guangzhou Sinogen Pharmaceutical Co., Ltd | Phase classification: P1 --> P1/2
Phase classification • Metastases
|
IL6 (Interleukin 6)
|
SalMet-Vec (SGN1)
11ms
Targeted deprivation of methionine with engineered Salmonella leads to oncolysis and suppression of metastasis in broad types of animal tumor models. (PubMed, Cell Rep Med)
RNA sequencing analyses reveal that the engineered Salmonella reduce the expression of a series of genes promoting cell growth, cell migration, and invasion. These findings point to a potential treatment modality for many metastatic solid tumors, which warrants further tests in clinical trials.
Preclinical • Journal
|
SalMet-Vec (SGN1)
11ms
Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor (clinicaltrials.gov)
P1, N=50, Recruiting, Guangzhou Sinogen Pharmaceutical Co., Ltd | Enrolling by invitation --> Recruiting
Enrollment status • Metastases
|
IL6 (Interleukin 6)
|
SalMet-Vec (SGN1)
11ms
Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor (clinicaltrials.gov)
P1, N=50, Enrolling by invitation, Guangzhou Sinogen Pharmaceutical Co., Ltd | Recruiting --> Enrolling by invitation
Enrollment status • Metastases
|
IL6 (Interleukin 6)
|
SalMet-Vec (SGN1)
1year
Study of SGN1 in Patients With Advanced Solid Tumor (clinicaltrials.gov)
P1, N=50, Recruiting, Guangzhou Sinogen Pharmaceutical Co., Ltd | Trial completion date: Jan 2024 --> Aug 2024 | Trial primary completion date: Sep 2023 --> Feb 2024
Trial completion date • Trial primary completion date • Metastases
|
IL6 (Interleukin 6)
|
SalMet-Vec (SGN1)
1year
Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor (clinicaltrials.gov)
P1, N=50, Recruiting, Guangzhou Sinogen Pharmaceutical Co., Ltd | Not yet recruiting --> Recruiting | Trial completion date: Apr 2025 --> Oct 2025
Enrollment open • Trial completion date • Metastases
|
IL6 (Interleukin 6)
|
SalMet-Vec (SGN1)
over1year
Study of SGN1 in Patients With Advanced Solid Tumor (clinicaltrials.gov)
P1, N=50, Recruiting, Guangzhou Sinogen Pharmaceutical Co., Ltd | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
IL6 (Interleukin 6)
|
SalMet-Vec (SGN1)
almost2years
Study of SGN1 in Patients With Advanced Solid Tumor (clinicaltrials.gov)
P1, N=50, Not yet recruiting, Guangzhou Sinogen Pharmaceutical Co., Ltd | Initiation date: Mar 2022 --> Sep 2022
Trial initiation date
|
IL6 (Interleukin 6)
|
SalMet-Vec (SGN1)
almost2years
Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor (clinicaltrials.gov)
P1, N=62, Not yet recruiting, Guangzhou Sinogen Pharmaceutical Co., Ltd | Initiation date: Mar 2022 --> Sep 2022
Trial initiation date
|
IL6 (Interleukin 6)
|
SalMet-Vec (SGN1)
over2years
Study of SGN1 in Patients With Advanced Solid Tumor (clinicaltrials.gov)
P1, N=50, Not yet recruiting, Guangzhou Sinogen Pharmaceutical Co., Ltd | Initiation date: Oct 2021 --> Mar 2022
Trial initiation date
|
IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL1B (Interleukin 1, beta)
|
SalMet-Vec (SGN1)
over2years
Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor (clinicaltrials.gov)
P1, N=62, Not yet recruiting, Guangzhou Sinogen Pharmaceutical Co., Ltd
Clinical • New P1 trial
|
CD8 (cluster of differentiation 8)
|
SalMet-Vec (SGN1)
over2years
Phase I Study of SGN1 in Patients With Advanced Solid Tumor (clinicaltrials.gov)
P1, N=50, Not yet recruiting, Guangzhou Sinogen Pharmaceutical Co., Ltd
Clinical • New P1 trial
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL1B (Interleukin 1, beta)
|
SalMet-Vec (SGN1)
Share via
